Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Valens Company Inc (The) Ordinary Shares VLNCF

The Valens Co Inc is a developer and manufacturer of cannabinoid-based products. The company's extraction methods are CO2, ethanol, hydrocarbon, solvent-less, and terpene extraction. Its products are Tinctures, Capsules, Beverages, and Vape cartridges among others. Its reportable segments are Cannabis operations, Analytical testing, and Corporate. The company has a business presence in Canada... see more

OTCQX:VLNCF - Post Discussion

View:
Post by lscfa on Jul 13, 2022 8:37pm

2023 guidance

Revenue & EBITDA Guidance 2023:
1. Minimum revenue of CAD$225 million
2. Adjusted EBITDA margins greater than 10%


225 x 10% / 109 mil diluted shs = $0.206 /sh

8 x $0.206 = $1.65 sh value

Comment by IFlyTheUnicorn on Jul 13, 2022 11:59pm
This post has been removed in accordance with Community Policy
Comment by Capharnaum on Jul 14, 2022 12:18am
They've been undelivering on what they promised for a while now.  They had $26M + an asset of $5M to be monetized (so $31M) and expect $10-12M cashflow loss from operations during Q3. They'll need a quick turnaround in Q4 and Q1 of next year, else it's looking like another financing round. Still, wishing the best to investors.
Comment by PUNJABI on Jul 14, 2022 9:17am
Revenue and EBITDA guidance 2023: Minimum revenue of $225-million; Adjusted EBITDA margins greater than 10 percent. They are still selling a dream and putting a positive spin. Look at their current Revenues and losses. Shares holders who have not learned a lesson yet, no one can help them. They have debt. At the current burn rate, they have cash for less than 2 quarters. Debt holders ...more  
Comment by IFlyTheUnicorn on Jul 14, 2022 9:23am
This post has been removed in accordance with Community Policy
Comment by flad101 on Jul 14, 2022 12:08pm
iSCFa your the biggest lying POS out here. 100% paid pumper.  Remember all the bs your talked about medipharm.   It now it's .07 cents.   Your such a clown.  And now your out here pumping away like before.  Either your the dumbest investor ever or your getting paid lots to spread lies.  Please no one believe this loser.  He is a complete idiot and should be ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities